JPRN-UMIN000005550已完成2 期
Randomized, open-label, multicenter trial to assess humanized anti-IL-6 receptor antibody, tocilizumab, for the treatment of systemic sclerosis - The assessment of tocilizumab for the treatment of systemic sclerosis
Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine0 个研究点目标入组 24 人开始时间: 2011年5月23日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
To explore the influence of the anti-interleukin-6 receptor antibody tocilizumab (TCZ) on patients with systemic sclerosis, we conducted a parallel group comparison study in three hospitals. At the end of 6 months, the average change in mRSS was larger in the TCZ group (6.3) than in the Conv group (3.4), but the difference was not statistically significant because of high variance in the TCZ group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) A patient who fit the careful administration criteria in the package insert of tocilizumab, except for interstitial pneumonitis 2) A patient who has applied a drug trial within six months 3) A patient who are using cyclophosphamide or has received intravenous cyclophosphamide infusion 4) A patient who are receiving or has received biologics
研究者
相似试验
已完成
4 期
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of SchizophreniaSchizophreniaSchizoaffective DisorderNCT02034474New York State Psychiatric Institute59
已完成
3 期
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDsRheumatoid ArthritisNCT00810277Hoffmann-La Roche14
终止
2 期
Efficacy of Early Administration of Tocilizumab in COVID-19 PatientsCOVID-19 PneumoniaNCT04346355Azienda Unità Sanitaria Locale Reggio Emilia126
已完成
3 期
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.Rheumatoid ArthritisNCT01988012Hoffmann-La Roche100
已完成
3 期
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDsRheumatoid ArthritisNCT00996606Hoffmann-La Roche58